Skip to main content

Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement

Written by Customer Service on . Posted in Public Companies.

Oslo, 4 August 2026: Reference is made to the resolution by the Annual General Meeting of Zelluna ASA (the “Company”) held on 23 April 2026, authorising the Company’s Board of Directors to increase the share capital by up to NOK 800,000 to settle amounts owed to Inven2 AS (“Inven2”) under an option and license agreement with the Company’s wholly owned subsidiary Zelluna Immunotherapy AS, upon dosing of the first patient in the first clinical trial for a licensed product. Reference is further made to the Company’s stock exchange announcement made on 13 July 2026, confirming that such dosing has now taken place.

On this basis, the Company’s Board of Directors has today resolved to increase the Company’s share capital by NOK 446,752, from NOK 29,413,759 to NOK 29,860,511, through the issuance of 446,752 new shares to Inven2 at a subscription price of NOK 19.7752 per share, each with a nominal value of NOK 1.00. The share contribution will be settled by set-off against the aggregate amount of EUR 791,666.70/NOK 8,834,604.54 owed to Inven2 under the option and license agreement.

Following registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the Company’s share capital will be NOK 29,860,511, divided into 29,860,511 shares, each with a nominal value of NOK 1.00.

For further information, please visit www.zelluna.com or contact:

Namir Hassan, CEO
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608

Geir Christian Melen, CFO
Email: geir.christian.melen@zelluna.com
Phone: +47 913 02 965

This information is published in accordance with the disclosure requirements set out in the Norwegian Securities Trading Act section 5-12.

About Zelluna ASA
Zelluna ASA (OSE: ZLNA) is a Company pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the world’s first MAGE-A4 targeting TCR-NK therapy in clinical development. Zelluna is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway and is listed on the Euronext Oslo Stock Exchange under the ticker ZLNA.
 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.